哈藥股份(600664.SH)234個品規進入國家醫保目錄
格隆匯8月21日丨哈藥股份(600664.SH)公佈,8月20日,國家醫療保障局、人力資源社會保障部印發《關於印發
<國家基本醫療保險>
的通知》(醫保發〔2019〕46號),正式公佈了國家基本醫療保險、工傷保險和生育保險常規准入部分的藥品名單。公司及控股子公司共有234個品規進入2019年國家醫保目錄。公司產品前列地爾注射液退出醫保目錄,雙黃連口服液從醫保乙類升甲類,重組人促紅素注射液(CHO細胞)醫保支付範圍擴大,注射用鹽酸頭孢替安醫保支付範圍受限。
國家基本醫療保險>
雙黃連口服液從醫保目錄乙類升為甲類和重組人促紅素注射液(CHO細胞) 醫保支付範圍擴大,將有利於產品的市場銷售。前列地爾注射液退出醫保目錄和注射用鹽酸頭孢替安醫保支付範圍受限,將對產品銷售產生不利影響,但不利影響在公司可控範圍內。公司將積極應對醫保目錄動態調整所帶來的市場變化,通過加強廣闊市場和第三終端開發,加快產品結構調整等方式,發揮政策利好優勢,化解政策不利因素,保持公司經營業績穩定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.